The Central Pharmaceutical Affairs Review Committee, a legal advisory body of the MFDS, also found that there was a controversy over the AstraZeneca (AZ) COVID-19 vaccine, which has been delayed for vaccination for 65-year-olds.

It is administered to adults over the age of 18, including those over 65, but there was an opinion that the elderly should specify that "the vaccination should be carefully decided" in the precautions for use.

However, no conclusions were drawn, including the recommendation of the MFDS’ Vaccination Committee to discuss whether to be vaccinated at the age of 65.
The MFDS released the minutes of the Advisory Meeting of the Central Pharmaceutical Affairs Rev